News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
HaluGen Life Sciences’ test evaluates an individual’s overall sensitivity and risk profile associated with psychedelic-assisted therapy
Vancouver, British Columbia–(Newsfile Corp. – June 10, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in the United States.
The Psychedelics Genetic Test Kit, a first of its kind, was designed and commercialized by HaluGen, and launched in Canada on April 5, 2021….